Forte Biosciences initiated with a Buy at Brookline

Brookline analyst Kumaraguru Raja initiated coverage of Forte Biosciences with a Buy rating and $4 price target. The analyst says FB-102 has potential in both autoimmune and immune diseases. FB-102 is expected to have a superior product profile compared to standard of care in graft versus host disease based on pre-clinical data, the analyst tells investors in a research note. The firm sees a favorable risk/reward on the shares as FB-102 advances through the clinic.